Stoke Therapeutics Is Unable To Derisk Its Platform (NASDAQ:STOK)



I covered Stoke Therapeutics (NASDAQ:STOK) in February, and although I was mildly positive, I am lucky I didn’t go out and buy the stock – because STOK is now down 40% after failing to make the grade in the phase 1/2 epilepsy trial I

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *